The behavioral dynamics of clinical trials
- 作者Howard Leventhal; David R. Nerenz; Elaine A. Leventhal; Richard R. Love; Lisa M. Bendena
- 卷第20卷
- 期第1期
- 文件大小1106.93KB
- 发表时间1991
- DOI10.1016/0091-7435(91)90014-u
- 页码132-146
Utility of C-Reactive Protein Measurement in Risk Stratification During Primary Cardiovascular Disease PreventionRobert L. Bard; Melvyn Rubenfire; Kim Eagle; Nicholas S. Clarke; Robert D. Brook · 2005
C-B4-04: Underuse of Aspirin in Women for Primary and Secondary Prevention of Cardiovascular Disease EventsRivera, C.; McNeal, C.; Song, J.; Varghese, J.; Ory, M. · Clinical Medicine & Research · 2010
High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular DiseaseGuijarro, Carlos · Circulation · 2001
High-Sensitivity C-Reactive Protein : Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular DiseaseRidker, P. M. · Circulation · 2001
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 updateTobe, Sheldon W.; Stone, James A.; Anderson, Todd; Bacon, Simon; Cheng, Alice Y.Y.; Daskalopoulou, Stella S.; Ezekowitz, Justin A.; Gregoire, Jean C.; Gubitz, Gord; Jain, Rahul; Keshavjee, Karim; Lindsay, Patty; L’Abbe, Mary; Lau, David C.W.; Leiter, Lawrence A.; O’Meara, Eileen; Pearson, Glen J.; Rabi, Doreen M.; Sherifali, Diana; Selby, Peter; Tu, Jack V.; Wharton, Sean; Walker, Kimberly M.; Hua-Stewart, Diane; Liu, Peter P. · Canadian Medical Association Journal · 2018
HighâSensitivity CâReactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC StudyQuispe, Renato; Michos, Erin D.; Martin, Seth S.; Puri, Rishi; Toth, Peter P.; Al Suwaidi, Jassim; Banach, Maciej; Virani, Salim S.; Blumenthal, Roger S.; Jones, Steven R.; Elshazly, Mohamed B. · Journal of the American Heart Association · 2020
Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*Ridker, P. M · Circulation · 2003
Most women at CVD risk do not take daily aspirinRivera CM, Song J, Copeland L, Buirge C, Ory M, McNeal CJ (2012) Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. J Womens Health 21: 379â87Linden, Bellnda · British Journal of Cardiac Nursing · 2012